Journal of Ayurveda and Integrative Medicine最新文献

Background: Lung cancer therapy resistance is often associated with the redox-regulatory nuclear factor erythroid 2-related factor-2 (NRF2)-Kelch-like ECH-associated protein1 (KEAP1) dysfunction.

Objective: This study investigated the impact of commercially available black tea (BT) phytochemicals (≥80 % theaflavins) from Camellia sinensis in sensitizing doxorubicin (Dox) against nonresponsive lung adenocarcinoma cells by modulation of non-canonical NRF2 regulators.

Methods: The methods included multidrug resistance (MDR) assay, comet assay, cell cycle analysis, zymography, semi-quantitative polymerase chain reaction, western blot and immunocytochemistry (ICC).

Results: BT pretreatment followed by Dox exposure was partially effective in Dox resistance-reversal in A549 cells by increasing drug uptake and downregulating MDR pumps. This combination induced DNA damage and cytotoxicity in A549 cells. It also reduced invasiveness and suppressed the expression of multidrug resistance protein-1, epidermal growth factor receptor, protein kinase B, and B cell lymphoma-2. In absence of wild-type KEAP1, non-KEAP1 regulators were thoroughly investigated by immunolocalization, and immunoblotting. BT restricted non-canonical NRF2 activators, such as p21 and apurinic/apyrimidinic endonuclease1 in A549 and acted oppositely in NCI-H23 cells. Additionally, NRF2-repressors, namely forkhead box O3, p53, glycogen synthase kinase-3β, and retinoid X receptor (RXR), were downregulated in NCI-H23 and upregulated in A549 cells. ICC exhibited that BT modulated the co-localization of NRF2 regulators, such as β-transducin repeat-containing protein and RXR, in A549 and NCI-H23 cells.

Conclusion: Therefore, it might be indicated that BT improved Dox retention and increased the Dox responsiveness in A549 cells. BT-mediated selective suppression of the NRF2, re-stabilized the KEAP-1-independent NRF2 regulators and made the non-responsive A549 cells partially sensitive to Dox.

Background: Utpalashatphala ghrita (USG) is a traditional ayurvedic medicine containing piperine as its main chemical constituent responsible for the activity. Murchita is an ayurvedic process to detoxify and purify the lipids (ghee, oil). It involves heating ghee with specific ayurvedic ingredients for a specified duration and temperature. It is essential to understand the stability of piperine during and after the murchita process.

Objective: The objective of this study was to develop and validate an LCMS method to assess the stability of piperine after the murchita process.

Method: LCMS system with electrospray ionization and ion-trap as the analyser was used to estimate the piperine content. Analysis was carried out in the multiple reaction monitoring (MRM) mode. Chromatographic mobile phase composed of a mixture of 55 % formic acid (0.1 %) in Milli-Q water (pH 3) and 45 % methanol. The LC-MS method was validated as per ICH Q2 (R2) guidelines. Stability of ghrita was assessed at various stability conditions.

Result: The developed LCMS method was accurate, precise and linear over a range of 0.5-32 μg/mL. LOQ of the method was 125 ng/mL and the run time was 10 min. Utpalashatphala ghrita (USG) and Murchita- Utpalashatphala ghrita (M-USG) were prepared as specified under Bhaishajya Ratnavali. Our study revealed that the murchita process degraded piperine by 26 %. However, the stability of piperine was found to be better in the murchita ghrita (M -USG), compared to the unprocessed USG.

Conclusion: Study effectively demonstrated that the murchita process enhanced the long-term stability of piperine.

Duchenne Muscular Dystrophy is a debilitating X-linked genetic disorder that manifests in early childhood with progressive muscle weakness, loss of ambulation, and ultimately, respiratory and cardiac failure resulting in premature mortality. A nine-year-old male patient presented with the inability to stand and ambulate without assistance, which had persisted since six years of age. He had been previously diagnosed with Duchenne Muscular Dystrophy, and his parents provided the relevant diagnostic documents. The patient exhibited weakness in the lower extremities, poor appetite, irregular bowel habits, and irritability. The clinical manifestations were evaluated from an Ayurvedic perspective, and a corresponding treatment plan was subsequently devised. The treatment regimen spanned 4 months, consisting of 6 sessions with an interval of 15-20 days between each clinical visit. The therapeutic approach encompassed major interventions such as external and internal Swedana, Basti, and oral medications. Concurrently, internal medications and appropriate dietary modifications were incorporated. The internal medications included herbs like Sida cordifolia L, Withania somnifera, Terminalia chebula Retz, Bacopa monneri, and Zingiber officinale Roxb. Additional herbs with proven Immunomodulatory, Antioxidant, and Anti-Inflammatory properties were also utilized. Physiotherapy was continued as part of the overall management strategy. Following the third treatment session, the child exhibited the ability to stand with the support of a cot, grasp and throw a stone - abilities that were not previously observed prior to the therapies. Additionally, by the end of the first month, improvements were noted in the patient's appetite and bowel habits. The comprehensive Ayurvedic approach, when combined with physiotherapy, demonstrated enhancements in symptoms such as relief from constipation, the capacity to stand with cot support, subtle changes in the upper limb muscle tone, and an overall enhancement in the child's quality of life. This study highlights the potential of Ayurveda as a complementary approach to conventional treatment.